GEOVAX LABS INC
NASDAQ: GOVX (GeoVax Labs, Inc.)
Last update: 5 minutes ago0.721
0.00 (0.56%)
| Previous Close | 0.717 |
| Volume | 704,231 |
| Price / Sales | 1.11 |
| Price / Book | 2.10 |
| 52 Weeks Range |
| Operating Margin (TTM) | -330.18% |
| Diluted EPS (TTM) | -2.80 |
| Current Ratio (MRQ) | 2.55 |
| Operating Cash Flow (TTM) | -24.68 M |
| Levered Free Cash Flow (TTM) | -16.53 M |
| Return on Assets (TTM) | -915.19% |
| Return on Equity (TTM) | -78,814.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | GeoVax Labs, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.83 |
|
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.42% |
| % Held by Institutions | 7.72% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |